|
|
||||||||
| Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology. |
From the Departments of Psychiatry (Dr. George, Dr. Nahas, Dr. Kozel, Mr. Anderson), Radiology (Dr. George, Dr. Bohning, Dr. Denslow), and Neurology (Dr. George, Mr. Anderson), Medical University of South Carolina, Charleston, SC. Drs. Chae, Lomarev, Li, and Mu are Visiting Research Scientists.
Address correspondence to Dr. Mark S. George, 502 North, IOP, Psychiatry Department, 67 President St., MUSC, Charleston, SC, 29425.
Article abstract Over the past 5 years, and especially within the last year, there has been a rapid expansion of vagus nerve stimulation (VNS)-related preclinical research, as well as clinical studies in indications other than epilepsy. The research advances in understanding VNS are occurring in the midst of a blossoming of other forms of therapeutic brain stimulation, such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and deep brain stimulation (DBS). In general, improved understanding of the neurobiological effects of VNS therapy as a function of the different use parameters (frequency, intensity, pulse width, duration, dose) is beginning to guide clinical use and help determine which diseases, in addition to epilepsy, VNS might treat.
This article has been cited by other articles:
![]() |
C. L. Harden The co-morbidity of depression and epilepsy: Epidemiology, etiology, and treatment Neurology, September 24, 2002; 59(90064): S48 - 55. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |